S
S

Sanofi

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Sanofi CEO: report on consumer unit in potential merger is 'gossip'

Sanofi CEO: report on consumer unit in potential merger is 'gossip' FRANKFURT, Feb 3 (Reuters) - Sanofi's chief executive SASY.PA on Friday dismissed suggestions that the French drugmaker's consumer healthcare business may become part of a merger deal with rivals. "We're running a very successful consumer business... The gossip around consumer makes me smile," said CEO Paul Hudson, when asked in an analyst call to comment on a recent report that Haleon HLN.L was looking into possible deals to bu
S

Regeneron profit beats estimates on Dupixent strength

UPDATE 2-Regeneron profit beats estimates on Dupixent strength Adds analyst estimates, background Feb 3 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea. Eylea, which recorded total sales of $9.65 billion in 2022, has been a key growth driver for the company ever since its launch more than a decade ago.
R
S

Sanofi’s ailments are more than skin deep

BREAKINGVIEWS-Sanofi’s ailments are more than skin deep The author is a Reuters Breakingviews columnist. The opinions expressed are their own. Refiles to fix grammar in paragraph one. LONDON, Feb 3 (Reuters Breakingviews) - Sanofi SASY.PA is battling multiple ailments. The $115 billion French pharma group on Friday forecast “low single digit” growth in earnings per share for 2023 , disappointing analysts.
G
N
S

Sanofi forecasts moderate profit growth on Dupixent demand

UPDATE 4-Sanofi forecasts moderate profit growth on Dupixent demand Sees "low single digit" percentage core EPS growth, FX adjusted Established MS pill faces competition from cheaper products Shares down 3%, lowest since mid-November CEO says Dupixent "mega-blockbuster" protected beyond 2031 Adds investor comment By Ludwig Burger Feb 3 (Reuters) - Sanofi SASY.PA forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be p
A
R
S

Sanofi Sees 2023 Low Single Digit Business Adjusted Growth

BRIEF-Sanofi Sees 2023 Low Single Digit Business EPS FX-Adjusted Growth Feb 3 (Reuters) - Sanofi SA SASY.PA : Q4 NET SALES EUR 10.73 BILLION VERSUS EUR 10.96 BILLION IN COMPANY-PROVIDED CONSENSUS END-2022 FREE CASH FLOW FLOW INCREASED 4.8% TO EUR 8,483 MILLION Q4 BUSINESS NET INCOME EUR 2.14 BILLION VERSUS EUR 2.13 BILLION IN COMPANY-PROVIDED CONSE
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.